The major histocompatibility complex class I (MHC-I) antigen presentation pathway is central to the adaptive immune response. In this process, intracellular proteins are degraded primarily by the ...

In a recent article posted to the bioRxiv* preprint server, researchers demonstrated the sarbecovirus open reading frame 7a (ORF7a)-induced hindrance of the antigen presentation by the major ...

Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer. This is an ASCO Meeting ...

Moreover, we found that two distinct DNA damaging drugs, the platinoid oxaliplatin and the topoisomerase inhibitor mitoxantrone, strongly up-regulate MHC-I AgPP in a manner dependent on activation of ...

Over the past decade, researchers have made great strides in the development and administration of cancer immunotherapies, which use the body's own immune system to treat disease. However, the ...